Compare
Sonoma Pharmaceuticals, Inc. vs Spectral AI, Inc. vs Nephros Inc vs Vivos Therapeutics, Inc.
| Latest fiscal year | Sonoma Pharmaceuticals, Inc. SNOA | Spectral AI, Inc. MDAI | Nephros Inc NEPH | Vivos Therapeutics, Inc. VVOS |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $19.53M | $19.65M | $18.79M | $17.44M |
| Revenue growth (YoY) | +36.7% | -33.6% | +32.7% | +16.0% |
| Gross margin | 38.0% | 45.4% | 61.9% | 60.4% |
| Operating margin | -12.6% | -43.8% | 6.1% | -114.1% |
| Net margin | -16.3% | -38.5% | 6.4% | -121.4% |
| Net income | -$3.17M | -$7.57M | $1.19M | -$21.17M |
| EPS (Diluted) | -$1.89 | -$0.29 | $0.11 | -$2.07 |
| Operating cash flow | -$3.93M | -$9.92M | $1.60M | -$15.26M |
| Free cash flow | -$4.12M | n/a | n/a | -$17.60M |
| Cash & equivalents | $2.40M | $15.40M | $5.40M | $2.03M |
| Total assets | $13.96M | $21.41M | $13.64M | $25.15M |
| Total liabilities | $10.87M | $27.13M | $3.44M | $26.70M |
| Shareholders' equity | $3.10M | -$5.73M | $10.20M | -$1.49M |
| Return on year-end equity | -102.6% | n/a | 11.7% | n/a |
| Shares outstanding | 1.80M | 30.69M | 10.64M | 9.29M |
Revenue, most recent five fiscal years
| Fiscal year | Sonoma Pharmaceuticals, Inc. | Spectral AI, Inc. | Nephros Inc | Vivos Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $19.53M Ended 2026-03-31 | $19.65M Ended 2025-12-31 | $18.79M Ended 2025-12-31 | $17.44M Ended 2025-12-31 |
| 1 year earlier | $14.29M Ended 2025-03-31 | $29.58M Ended 2024-12-31 | $14.16M Ended 2024-12-31 | $15.03M Ended 2024-12-31 |
| 2 years earlier | $12.73M Ended 2024-03-31 | $18.06M Ended 2023-12-31 | $14.24M Ended 2023-12-31 | $13.80M Ended 2023-12-31 |
| 3 years earlier | $13.27M Ended 2023-03-31 | $25.37M Ended 2022-12-31 | $9.97M Ended 2022-12-31 | $16.02M Ended 2022-12-31 |
| 4 years earlier | $12.63M Ended 2022-03-31 | n/a | $10.22M Ended 2021-12-31 | $16.89M Ended 2021-12-31 |